Related
Gene Tan is an assistant professor at the J. Craig Venter Institute working in the Infectious Disease group. The focus of his research is on virus-host interactions by defining the immunological, molecular and genetic determinants that govern immunity and disease. The aim is to better understand how viruses manipulate the host machinery to replicate and in turn elucidate the mechanisms by which the host counteracts the pathogen. Analyses of virus-host interaction can then facilitate the development of better diagnostic tools, novel therapeutics and vaccines.
Prior to his appointment at JCVI, Dr. Tan was a postdoctoral fellow at the Icahn School of Medicine at Mount Sinai working on characterizing the immunological and structural determinants of protection against influenza virus and Zika virus. He received his doctorate from Thomas Jefferson University and his undergraduate degree from the Philadelphia College of Pharmacy and Science.
Patents
Vaccines for use in the prophylaxis and treatment of influenza virus disease (Pat. No. US20170114103)
Research Priorities
Characterization of the structural and immunological determinants of protection against viral pathogens:
- Elucidate the mechanisms by which antibodies neutralize virus and protect in vivo.
- Emphasis on developing novel methods in isolating monoclonal antibodies from human peripheral blood mononuclear cell (PBMC) compartment.
Characterization of virus-host interaction by defining the molecular and transcriptional response
- Emphasis on respiratory and neurotropic pathogens.
Publications
Influenza A Viruses in Whistling Ducks (Subfamily Dendrocygninae).
Viruses. 2021-01-28; 13.2:
PMID: 33525360
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Advanced drug delivery reviews. 2021-01-20; 172.314-338.
PMID: 33482248
Proinflammatory IgG Fc structures in patients with severe COVID-19.
Nature immunology. 2021-01-01; 22.1: 67-73.
PMID: 33169014
Collective interactions augment influenza A virus replication in a host-dependent manner.
Nature microbiology. 2020-09-01; 5.9: 1158-1169.
PMID: 32632248
Author Correction: Microbiome disturbance and resilience dynamics of the upper respiratory tract during influenza A virus infection.
Nature communications. 2020-06-16; 11.1: 3132.
PMID: 32546784
Microbiome disturbance and resilience dynamics of the upper respiratory tract during influenza A virus infection.
Nature communications. 2020-05-21; 11.1: 2537.
PMID: 32439901
Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model.
mBio. 2020-03-24; 11.2:
PMID: 32209676
Innate Immune Response to Influenza Virus at Single-Cell Resolution in Human Epithelial Cells Revealed Paracrine Induction of Interferon Lambda 1.
Journal of virology. 2019-10-15; 93.20:
PMID: 31375585
Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
Nature communications. 2018-10-11; 9.1: 4223.
PMID: 30310067
Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice.
Nature communications. 2017-10-10; 8.1: 846.
PMID: 29018261
Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus.
Proceedings of the National Academy of Sciences of the United States of America. 2016-10-18; 113.42: 11931-11936.
PMID: 27698132
Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact.
Proceedings of the National Academy of Sciences of the United States of America. 2016-10-04; 113.40: E5944-E5951.
PMID: 27647907
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.
Cell host & microbe. 2016-06-08; 19.6: 800-13.
PMID: 27281570
Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.
PLoS pathogens. 2016-04-01; 12.4: e1005578.
PMID: 27081859
Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins.
Journal of virology. 2016-01-13; 90.7: 3789-93.
PMID: 26764009
Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
Antimicrobial agents and chemotherapy. 2015-07-01; 59.7: 4162-72.
PMID: 25941218
Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.
The Journal of clinical investigation. 2015-03-02; 125.3: 1255-68.
PMID: 25689254
Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.
Journal of virology. 2014-12-01; 88.23: 13580-92.
PMID: 25210195
Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.
Nature medicine. 2014-02-01; 20.2: 143-51.
PMID: 24412922
A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo.
Journal of virology. 2012-06-01; 86.11: 6179-88.
PMID: 22491456
The dynein light chain 8 binding motif of rabies virus phosphoprotein promotes efficient viral transcription.
Proceedings of the National Academy of Sciences of the United States of America. 2007-04-24; 104.17: 7229-34.
PMID: 17438267
Genomics of Zika Virus
Investigating the genomics of Zika virus throughout the Americas
Genomics of West Nile Virus
Sequencing West Nile virus genomes isolated in the United States
Genomics of Influenza A and Influenza B Viruses
Sequencing Influenza genomes isolated from various hosts and locations
Genomics of Respiratory Syncytial Virus
Sequencing clinical isolates of Respiratory Syncytial Virus in various locations
Antigenic Map of Lyssavirus (Rabies Virus)
Vaccines and Therapeutics for Zika
Genomics of Chikungunya Virus
Sequencing Chikungunya virus genomes isolated from the Western hemisphere during the 2014 Caribbean outbreak
Coronavirus Research
Overview of various projects related to the novel coronavirus pandemic.A Bioinformatics Roadmap for the Human Vaccines Project
Age-Associated Determinants of Alveolar Macrophage-Mediated Antiviral and Inflammatory Responses
Engineering a Self-Amplifying RNA Amplicon as a Vaccine or Therapeutic for Influenza
Investigating Viral Disease to Develop Next Generation Vaccines and Therapeutics
Virus Pathogen Resource (ViPR)
Influenza Research Database (IRD)
Respiratory Syncytial Virus: Host-Virus-Microbiome Interactions
Genetic Diversity and Evolutionary Dynamics of Influenza A and B Viruses
Genetic Diversity and Evolutionary Dynamics of Eastern Equine Encephalitis Viruses (EEEV)
Genetic Diversity and Evolutionary Dynamics of Respiratory Syncytial Viruses (RSV)
Genetic Diversity and Evolutionary Dynamics of Rotaviruses
Impact of Viral Intra-Host Diversity on Transmission Dynamics and Antiviral Resistance
Genetic Diversity and Evolutionary Dynamics of West Nile Viruses
Influenza: Host-Virus-Microbiome Interactions
Genomics of Eastern Equine Encephalitis Virus
Elucidating transmission of EEEV in the United States
23-Nov-2020
Blog
Unique Antibody Pattern Discovered in COVID-19 ICU Patients May Be Key to Predicting Severe Outcomes
29-Oct-2020
Blog
COVID-19 Further Complicating Flu Season
05-Nov-2018
Blog